Cardiology Update 2013
Treatment Recommendations in Non Valvular Atrial Fibrillation John Camm St. George’s University of London United Kingdom Advisor / Speaker : Astra Zeneca, Gilead, Merck, Menarini, Sanofi Aventis, Servier, Xention, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi, Pfizer, Boston Scientific, Biotronik, Medtronic, St. Jude Medical, Actelion, GlaxoSmithKline, InfoBionics, Incarda, Johnson and Johnson, Mitsubishi, Novartis, Takeda
Guidelines for AF Management
ESC Guidelines: Camm J et al. Eur Heart J 2010;31:2369–429; ACCF/AHA/HRS Guidelines: Wann LS et al. J Am Coll Cardiol 2011;57:1330–7; CCS Guidelines: Skanes AC et al. Can J2Cardiol 2012;28:125– 136; You JY et al. ACCP Guidelines: Chest 2012;141;e531S–e575S; http://www.nice.org.uk/ta249
Anticoagulation - General Recommendations for prevention of thromboembolism in nonvalvular AF - general Recommendations
Class
Level
Antithrombotic therapy to prevent thromboembolism is recommended for all patients with AF, except in those patients (both male and female) who are at low risk (aged